About the ABPI

The ABPI represents innovative resea​rch-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.

Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.

Globally our industry is researching and developing more than 7,000 new medicines.

The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.​​​​​​​

Notes to editors

  1. Haseeb Ahmad joined Novartis in February 2017 and was elected to the ABPI Board shortly after.  In his prior role with MSD, as Managing Director for Greece, he delivered significant growth through a period of major economic upheavals, he also led the relevant industry association, the American Chamber of Commerce Pharma Group. During his twenty-year career, Haseeb has held progressively senior in-country and above-country roles in Strategy, Operations, Sales and Marketing. Haseeb has previously led the American Chamber of Commerce Pharma Group, is a member of Novartis European Executive Committee.
  2. Hugo Fry is Managing Director of Sanofi UK and is already a member of the Board of Management of the ABPI. Hugo has held central strategic positions and commercial operational roles, most recently as Chief Marketing Officer for Sanofi Pasteur MSD (SPMSD), leading the commercial effort for the European vaccine Joint Venture. Prior to this, Hugo spent four years in Russia leading Sanofi’s Diabetes, Oncology, Cardiovascular, Internal Medicine and Consumer Healthcare businesses. He was then appointed General Manager of Zentiva Russia, where he was instrumental in maintaining Zentiva as one of the fastest growing companies in Russia while integrating into the Sanofi Group. Hugo then joined the Sanofi Diabetes Leadership Team before assuming his role at SPMSD. 

Media enquiries


+44 (0) 20 7747 7147​​